Effect of Diosmin/Hesperidin Combination on Platinum Compounds-Induced Nephropathy in Cancer Patients
ConditionCancer Patients
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBeni-Suef University
About this trial
The current study aims to investigate the protective properties of diosmin/hesperidin on cisplatin-induced nephrotoxicity.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients of 18 to 75 year-age must have histologically or cytologically confirmed cancer by the Laboratory of Pathology receiving a platinum compound chemotherapy.
Disqualifiers
-History of allergic reactions attributed to drugs in the study.
Pregnant women.
Life expectancy less than 6 months
Inability or unwillingness to comply with research protocols.
Trial design
Design model
Single group
Treatments tested in this trial
diosmin/hesperdin
Combination productcombination of Diosmin and Hesperidin
Treatment groups
100 Participants
are divided into 1 treatment groupGroup A: controlExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
serum creatinine level
Serum creatinine will be measured in mg/dl every 2 weeks during the study period.
Time frame
6 months following treatment2
blood urea level
blood urea levels will be measured in mg/dl every 2 weeks during the study period.
Time frame
6 months following treatmentSecondary outcomes
1
hemoglobin level
Hemoglobin levels will be measured in g/dl every 2 weeks during the study period.
Time frame
6 months following treatmentSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov